PRN: Profiles of the Top 200 Developers of In-Vitro Diagnostics Tests for Cancer & Infectious Diseases 2017 - Research and Markets
01/mar/2017 16:45:10 PR Newswire Turismo Contatta l'autore
Profiles of the Top 200 Developers of In-Vitro Diagnostics Tests for Cancer & Infectious Diseases 2017 - Research and Markets |
[01-March-2017] |
DUBLIN, Mar 01, 2017 /PRNewswire/ -- Research and Markets has announced the addition of the "The Top 200 Developers of In-Vitro Diagnostics Tests for Cancer & Infectious Diseases" report to their offering. Did you know? - Lewis Stuart is Vice President, Sales & Marketing, U.S. Breast/Colon at Genomic Health, Inc.. These are just a tiny sample of the 1,000's of facts to be found in The Top 200 Developers Of In-Vitro Diagnostics Tests For Cancer & Infectious Diseases'. This unique and comprehensive report (360 pages) identifies and profiles the leading 200 developers of in-vitro diagnostics tests for cancer and infectious diseases. They are located right across the globe from the United States and Europe to India and China. Report Target Market: 1) In-Vitro Diagnostics Companies 2) Suppliers 3) Distributors 4) Industry Associations: Most people will be aware of some of the major developers of in-vitro diagnostics tests for cancer and infectious diseases such as Accugenomics, Inc., Agendia Inc., altona Diagnostics GmbH, Biocept, Inc., bioLytical Laboratories Inc., GeneNews Limited, HiberGene Diagnostics and OvaGene Oncology, Inc. but this major new report looks at all 100 of the top companies. For more information about this report visit http://www.researchandmarkets.com/research/ck84q9/the_top_200 Media Contact: Laura Wood, Senior Manager  |